Table 1.

Univariate survival analysis in TCGA-LGG dataset.

	OS			DSS			DFI			PFI
	HR	95%CI	p value	HR	95%CI	p value	HR	95%CI	p value	HR	95%CI	p value
MAGEH1 expression	0.342	0.233–0.503	0.000*	0.304	0.200–0.461	0.000*	0.448	0.183–1.098	0.079	0.439	0.327–0.590	0.000*
MAGED1 expression	0.951	0.669–1.353	0.784	1.001	0.690–1.450	0.994	1.195	0.494–2.892	0.692	0.967	0.727–1.285	0.818
Histology
OA vs. O (Ref.)	1.080	0.656–1.776	0.761	1.022	0.597–1.752	0.934	0.548	0.159–1.879	0.339	0.832	0.556–1.244	0.372
A vs. O (Ref.)	1.782	1.192–2.663	0.005*	1.902	1.248–2.899	0.003*	1.009	0.374–2.716	0.986	1.605	1.165–2.212	0.004*
Grade
III vs. II (Ref.)	3.093	2.033–4.705	0.000*	3.187	2.039–4.981	0.000*	0.692	0.280–1.707	0.424	1.554	1.143–2.112	0.005*
IDH status
IDH MUT vs. WT (Ref.)	0.153	0.105–0.222	0.000*	0.134	0.091–0.198	0.000*	0.223	0.074–0.673	0.008*	0.173	0.125–0.238	0.000*
1p/19q Co-deletion status
Present vs. Absent (Ref.)	0.393	0.245–0.628	0.000*	0.368	0.222–0.610	0.000*	0.496	0.165–1.485	0.21	0.437	0.307–0.622	0.000*
MGMT promoter methylation status
Present vs. Absent (Ref.)	0.388	0.265–0.569	0.000*	0.349	0.235–0.518	0.000*	0.817	0.239–2.790	0.747	0.423	0.307–0.582	0.000*
Age (increasing years)	1.058	1.042–1.075	0.000*	1.059	1.042–1.076	0.000*	1.028	0.992–1.066	0.122	1.028	1.016–1.040	0.000*
Gender
Female vs. Male (Ref.)	0.912	0.619–1.342	0.641	0.899	0.598–1.353	0.613	1.190	0.483–2.934	0.705	1.164	0.858–1.577	0.327

OS, overall survival; DSS, disease specific survival; DFI, disease free interval; PFI, progression free interval; HR, hazard ratio; CI, confidence interval; O, oligodendroglioma; OA, oligoastrocytoma; A, astrocytoma; WT, wild type; MUT, mutant, MGMT; O-6-methylguanine-DNA methyltransferase. * indicates p < 0.05.